| |
|
|
|
GTC, USA
2013/4/29
GTC’s 3rd Diabetes Summit on April 29 - April 30, 2013 in Boston, MA is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. As well as providing updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics.
| We look forward to seeing you at the conference! | | | | | | | Conference Date: April 29-30, 2013
|
|
|
|
|
|
|
|
Organized by:
|
|
GTC |
|
|
Invited Speakers:
|
|
| KEYNOTE SPEAKER |  | Riccardo Perfetti
Vice President, Global Medical Affairs
Sanofi | | FEATURED SPEAKER |  |  |  | Allan Ertmann Karlsen
Corporate Vice President
Diabetes Biology &
Hagedorn
Research Institute
Diabetes Research Unit
Novo Nordisk A/S | G. Steven Burrill
CEO
Burrill & Company | Ed Damiano
Associate Professor
Biomedical Engineering
Boston University |
|
| | | DISTINGUISHED SPEAKERS AND PANELISTS | | | Mostafa Analoui
Head; Healthcare and Life Sciences
The Livingston Group
Barbara Corkey
Vice Chair for Research
Boston University School of Medicine
John Mc Elroy
President and CSO
Jenrin Discovery
Kurt Graves
Executive Chairman & CEO
Intarcia Therapeutics
Bart Henderson
President & Founder
Rhythm
George Kunos
Scientific Director
NIAAA/NIH
Tomas Landh
Director, Stragegy and Sourcing, Diabetes Research Unit
Novo-Nordisk
Randall Nelson
Research Professor, Molecular Biomarkers Lab
Arizona State University
Karen Segal
Senior Vice President
Diabetes and Metabolic Diseases
Meso Blast
Lauren Shearman
Strategic Licensing & Acquisitions Lead
Diabetes & Endocrinology
External Scientific Affairs
Worldwide Licensing & Acquisitions
Merck
Peter Stein
Head; Development Metabolism
Janssen R&D US
Solomon Steiner
Managing Director
Steiner Ventures
Jim Wang
VP, Cardiovascular and Metabolic Diseases Research
Crown Bioscience (Taicang) Inc.
Advisory Board Members Helping to Organize the Event
Paul Burton
Vice President, Franchise Medical Leader
Johnson and Johnson Pharmaceutical Research Division
Richard Caroddo
Business Development Executive
Medpace
Steven Cohen
Senior Director
Daiichi Sankyo
Lisa Jansa
Chief Executive Officer
Exsulin Corporation
Allan Ertmann Karlsen
Vice President
Novo-Nordisk
Urban Kiernan
Senior Scientist
Thermo Fischer
Christopher Kiritsy
President and Chief Executive Officer, Co-Founder
Arisaph Pharmaceuticals
Tomas Landh
Director, Strategy and Sourcing, Diabetes Research Unit
Novo Nordisk
James Lenhard
Research Fellow
Johnson & Johnson
Yin Liang
Head of In Vivo Section
Johnson & Johnson
Jeffrey Pfefferkorn
Senior Principal Scientist
Pfizer
David Warnock
Professor
School of Medicine at the University of Alabama at Birmingham
Jim Wang
VP, Cardiovascular and Metabolic Diseases Research
Crown Bioscience (Taicang) |
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2013/4/29
|
|
|
|
|
|
|
|
Registration:
|
|
https://www.gtcbio.com/index.php?option=com_register&cn=Diabetes%20Summit%202013&cid=115
|
|
|
E-mail:
|
|
Scott.Mccue@gtcbio.com
|
|
|
|
|
|
|
|
|